126712-07-0

Basic information

• Product Name: 3-Bromo-2-formylanisole
• Synonyms: 3-Bromo-2-formylanisole
• CAS NO: 126712-07-0
• Molecular Formula: C₈H₇BrO₂
• Molecular Weight: 215.05
• Mol File: 126712-07-0.mol

Chemical Properties

• Melting Point: 41-42 °C
• Boiling Point: 276.0±20.0 °C(Predicted)
• Appearance: /
• Density: 1.522±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: 3-Bromo-2-formylanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-formylanisole(126712-07-0)
• EPA Substance Registry System: 3-Bromo-2-formylanisole(126712-07-0)

Safety Data

• Hazardous Substances Data: 126712-07-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Bromo-2-formylanisole is utilized as a key intermediate in organic synthesis, particularly for the production of pharmaceuticals and agrochemicals. Its bromine atom and formyl group contribute to its versatility in forming a variety of biologically active compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 3-Bromo-2-formylanisole is employed as a building block for synthesizing complex organic molecules with potential therapeutic applications. Its unique structural features facilitate the creation of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
3-Bromo-2-formylanisole also finds application in the agrochemical industry, where it serves as an intermediate for the synthesis of pesticides and other crop protection agents. Its chemical properties allow for the development of effective and targeted agrochemicals.
Used in Fragrance and Flavoring Industry:
3-Bromo-2-formylanisole is used as a component in the manufacture of fragrances and flavoring agents. Its distinct chemical structure imparts unique olfactory and gustatory properties, making it a valuable ingredient in the creation of novel and appealing scents and tastes.

Upstream product

• 22532-61-2 2-bromo-6-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 
• 135-02-4 ortho-anisaldehyde 
• 124639-28-7 2-(2-methoxyphenyl)-1,3-dimethylimidazolidine 
• 591-20-8 3-Bromophenol 
• 107369-63-1 2-methoxybenzaldehyde O-methyloxime 
• 67-56-1 methanol 
• 6630-33-7 ortho-bromobenzaldehyde 
• 61042-21-5 (E)-2-methoxybenzaldehyde O-methyl oxime 
• 1314031-76-9 (E)-2-bromo-6-methoxybenzaldehyde O-methyl oxime 
• 360575-28-6 2-bromo-6-fluorobenzaldehyde 
• 124-41-4 sodium methylate 
• 1073-06-9 3-fluorobromobenzene 

Downstream Products

• 139102-36-6 1-Bromo-3-methoxy-2-((E)-2-nitro-propenyl)-benzene 
• 1400592-76-8 C₃₉H₅₄BrN₃O₆Si 
• 946614-48-8 methyl 2-(2-(cyanomethyl)-6-methoxy-4-methylphenyl)acetonitrile 
• 830-54-6 8-methoxy-3-methyl-1H-isochromen-1-one 
• 75115-29-6 2-Methoxy-6-(2-oxo-propyl)-benzoic acid 
• 22532-61-2 2-bromo-6-hydroxybenzaldehyde 
• 31786-45-5 2-bromo-6-methoxybenzoic acid 

Relevant articles and documents

TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X11 and X22 are independently C or N, provided that zero or one of X11 and X22 is N; Ring A represented by the structure is: or; and Q, R11, R22, R33, R44, R66, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Dihydroisocoumarin derivative and preparation method and application thereof

The present invention discloses a dihydroisocoumarin derivative and preparation method and application thereof, the dihydroisocoumarin derivative having a structure as shown in formula (I) or (II). The method of preparing dihydroisocoumarin derivatives of

Dihydroisocoumarin derivative and preparation method and application thereof

The present invention discloses a dihydroisocoumarin derivative and preparation method and application thereof, the dihydroisocoumarin derivative having a structure as shown in formula (I) or (II). The method of preparing dihydroisocoumarin derivatives of

ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF

Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

Atroposelective Synthesis of Axially Chiral 4-Aryl α-Carbolines via N-Heterocyclic Carbene Catalysis

The first catalytic asymmetric construction of axially chiral 4-aryl α-carboline skeletons has been accomplished through an N-heterocyclic carbene (NHC)-catalyzed atroposelective formal [3 + 3] annulation of 4-nitrophenyl 3-arylpropiolates with 2-sulfonamidoindolines. The synthetic utility of the title compounds has been demonstrated by the diverse late-stage structural modifications. Density functional theory calculations were also conducted to illuminate the key factors for controlling the origin of the enantioselectivity. This strategy not only provides an efficient pathway to access axially chiral α-carboline atropisomers but also offers a novel catalytic enantioselective mode for the construction of axially chiral heterobiaryls by using NHC-bound alkynyl acylazoliums.

Monodentate Transient Directing Group Enabled Pd-Catalyzed Ortho-C-H Methoxylation and Chlorination of Benzaldehydes

We report Pd-catalyzed ortho-C-H methoxylation and chlorination of benzaldehydes by employing monodentate transient directing groups (TDGs) as an alternative strategy to bidentate TDGs. More importantly, a single crystal of benzaldehyde imine ortho-cyclopalladium intermediate was successfully obtained, and its structure was unambiguously determined by X-ray diffraction, which clearly showed that it was a binuclear palladium species bridged by a pyridone ligand. The utility of this approach was further demonstrated through the synthesis of key intermediates of natural products and drugs.

Selective ortho -bromination of substituted benzaldoximes using Pd-catalyzed C-H activation: Application to the synthesis of substituted 2-bromobenzaldehydes

Substituted 2-bromobenzaldehydes were synthesized from benzaldehydes using a three-step sequence involving a selective palladium-catalyzed ortho-bromination as the key step. O-Methyloxime serves as a directing group in this reaction. A rapid deprotection of substituted 2-bromobenzaldoximes afforded substituted 2-bromobenzaldehydes with good overall yields.

SYNTHESIS OF THE POTENT IMMUNOSUPPRESSANT AGENTS DALESCONOL A AND B

This invention relates to compounds having the structure: wherein bonds α, β, γ, δ, ω, η, χ, ε, κ, and μ are each present or absent, and R1-R18 are various substituents described herein.

First total synthesis of Papilistatin

Papilistatin has been isolated recently and found to have good anticancer and antibacterial activity. Papilistatin is a unique phenanthrene-1,10- dicarboxylic acid. The first total synthesis of papilistatin is described here with radical cyclisation as the key step.

Total syntheses of dalesconol A and B

(Chemical equation Presented) (Chemical equation Presented) A polycyclic collapse: Use of a carefully designed acyclic intermediate participated in a cascade reaction that formed the entire core of the polyketide-derived dalesconols in a single flask (see scheme). A number of additional and carefully controlled synthetic operations completed an expeditious synthesis of both of these highly bioactive natural products as well as structural congenors.